Gaudium IVF and Women Health Ltd
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India.[1]
- Market Cap ₹ 838 Cr.
- Current Price ₹ 115
- High / Low ₹ 133 / 69.2
- Stock P/E 45.5
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 47.8 %
- ROE 51.6 %
- Face Value ₹ 5.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 50.0%
Cons
- Debtor days have increased from 87.3 to 146 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 44 | 46 | 59 | |
| 24 | 27 | 31 | |
| Operating Profit | 20 | 19 | 28 |
| OPM % | 45% | 41% | 48% |
| 0 | 0 | 0 | |
| Interest | 0 | 1 | 2 |
| Depreciation | 1 | 2 | 2 |
| Profit before tax | 18 | 16 | 25 |
| Tax % | 26% | 38% | 25% |
| 13 | 10 | 19 | |
| EPS in Rs | 133.91 | 100.28 | 3.03 |
| Dividend Payout % | 48% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 50% |
| Last Year: | 52% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 31 |
| Reserves | 22 | 26 | 15 |
| 10 | 17 | 21 | |
| 2 | 7 | 9 | |
| Total Liabilities | 35 | 51 | 75 |
| 16 | 18 | 18 | |
| CWIP | 0 | 0 | 7 |
| Investments | 1 | 1 | 6 |
| 18 | 31 | 44 | |
| Total Assets | 35 | 51 | 75 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 24 | 3 | 8 | |
| -14 | -5 | -15 | |
| 4 | -1 | 2 | |
| Net Cash Flow | 13 | -3 | -5 |
| Free Cash Flow | 11 | 1 | -0 |
| CFO/OP | 145% | 28% | 46% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 7 | 108 | 146 |
| Inventory Days | 101 | 141 | 170 |
| Days Payable | 83 | 85 | 99 |
| Cash Conversion Cycle | 26 | 164 | 218 |
| Working Capital Days | -54 | -22 | 46 |
| ROCE % | 44% | 48% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015
1d - NCLT New Delhi rejected Ramaa Capital's insolvency petition against Gaudium IVF; order dated May 15, received May 22, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Gaudium IVF schedules Q4 and FY26 earnings call for May 29, 2026 at 12:00 PM IST.
-
Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of The Audited Standalone And Consolidated Financial Statements/Results Of The Company For The Quarter And Year Ended March 31 2026.
2d - Board meeting on May 28, 2026 to approve audited Q4 and FY26 results; trading window closed.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15 May - Monitoring Agency Report for quarter ended March 31, 2026; no deviation, Rs 8.69 crore utilised, Rs 81.31 crore unutilised.
-
Clarification On Price Movement
16 Apr - Company clarified price movement was market-driven and disclosed no new price-sensitive information.
Business Profile[1][2]
The company operates in the Assisted Reproductive Technology (ART) and IVF segment in India, following a hub-and-spoke model across 30+ locations (7 hubs and 28 spokes). It also runs a 15-bed day-care hospital in Janakpuri (Delhi NCR) and operates an in-house pharmacy through its wholly owned subsidiary, Gaudium International Pvt. Ltd.